Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Stock Now Rated "Moderate Buy" by Wall Street Brokerages

Key Points

• Analyst consensus is “Moderate Buy”: Five firms covering Nautilus Biotechnology issued one sell, one hold, two buy and one strong-buy rating, with an average 12-month price target of $3.83 versus the stock’s $2.44 opening price.
• Institutional ownership remains significant: Institutional investors own 50.71% of NAUT, with BlackRock initiating a roughly $5.0 million position and Susquehanna increasing its holdings by 1,710.9%.
• The company remains unprofitable but beat quarterly expectations: Nautilus reported a quarterly loss of $0.11 per share, better than the expected $0.14 loss, while revenue of $0.19 million exceeded estimates of $0.10 million.

Shares of Nautilus Biotechnology, Inc. (NASDAQ:NAUT - Get Free Report) have received an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, one has given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $3.83.

NAUT has been the topic of several analyst reports. Weiss Ratings lowered shares of Nautilus Biotechnology from a "sell (d-)" rating to a "sell (e+)" rating in a research note on Wednesday, August 5th. Zacks Research raised shares of Nautilus Biotechnology to a "hold" rating in a research note on Wednesday, September 30th. Leerink Partners assumed coverage on shares of Nautilus Biotechnology in a report on Wednesday, September 9th. They issued an "outperform" rating and a $4.00 price objective for the company. Finally, Roth Capital assumed coverage on Nautilus Biotechnology in a report on Tuesday, September 29th. They set a "buy" rating and a $3.50 target price on the stock.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in NAUT. BlackRock Inc. acquired a new stake in Nautilus Biotechnology in the 2nd quarter worth approximately $5,025,000. Susquehanna International Group LLP boosted its position in Nautilus Biotechnology by 1,710.9% during the second quarter. Susquehanna International Group LLP now owns 890,949 shares of the company's stock worth $1,666,000 after purchasing an additional 841,749 shares during the period. Dimensional Fund Advisors LP boosted its position in Nautilus Biotechnology by 15.3% during the first quarter. Dimensional Fund Advisors LP now owns 329,123 shares of the company's stock worth $1,274,000 after purchasing an additional 43,684 shares during the period. Renaissance Technologies LLC grew its holdings in Nautilus Biotechnology by 2.2% during the first quarter. Renaissance Technologies LLC now owns 265,700 shares of the company's stock valued at $1,031,000 after purchasing an additional 5,800 shares during the last quarter. Finally, Corient Private Wealth LP acquired a new position in Nautilus Biotechnology during the second quarter valued at approximately $308,000. 50.71% of the stock is owned by institutional investors.

Nautilus Biotechnology Stock Performance

Shares of NAUT opened at $2.44 on Tuesday. The firm has a market cap of $310.49 million, a PE ratio of -5.42 and a beta of 0.73. The firm's 50 day moving average price is $1.42 and its 200 day moving average price is $2.09. Nautilus Biotechnology has a twelve month low of $0.84 and a twelve month high of $4.31.

Nautilus Biotechnology (NASDAQ:NAUT - Get Free Report) last posted its earnings results on Monday, July 27th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.14) by $0.03. The business had revenue of $0.19 million during the quarter, compared to analyst estimates of $0.10 million. On average, sell-side analysts anticipate that Nautilus Biotechnology will post -0.52 earnings per share for the current fiscal year.

Nautilus Biotechnology Company Profile

Nautilus Biotechnology, Inc is a biotechnology company developing technologies for large-scale protein analysis, also known as proteomics. Its goal is to enable researchers to identify and quantify proteins more comprehensively, helping advance drug discovery, biological research and the development of precision medicine.

The company's principal offering is the Nautilus Proteome Analysis Platform, an integrated system that combines specialized instrumentation, consumables and software.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.